Acimtamig
Based on 1 Customer Validation
Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL).
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 2738880-26-5
- Molecular Weight:103.936 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
TNFRSF8 & FCGR3A
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD30/TNFRSF8 Protein, Human (HEK293, His, HY-P70023) can bind Acimtamig. The EC50 for this effect is 668.7 ng/mL. -
Immobilized Fc gamma RIIIA/CD16a Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78099) can bind Acimtamig. The EC50 for this effect is 714.0 ng/mL.
Product Details
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.9%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics TCE (T cell engager) Potential in Solid Tumors
T-cell engagers (TCEs) are engineered immunotherapeutic molecules designed to redirect endogenous T cells toward tumor cells through simultaneous binding of a T-cell receptor component, most commonly CD3, and a tumor-associated antigen (TAA) expressed on malignant cells.
2026-06-18
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)